Latest News Archive
Please select Category, Year, and then Month to display items
16 April 2024
|
Story Anthony Mthembu
|
Photo Supplied
Melanie Ridgard celebrates receiving a Master of Business Administration (MBA) at the graduation ceremony held at the UFS Bloemfontein campus on 19 April 2024.
In the realm of self-development, few stories are as inspiring as that of Melanie Ridgard, the Interim Administration and Events Coordinator at the South African Research Chair in Industrial Development (SARChI-ID) at the University of Johannesburg (UJ). Ridgard’s forthcoming graduation with a Master in Business Administration (MBA) on 19 April 2024 from the University of the Free State (UFS) marks not only a personal triumph but also a testament to the transformative power of higher education.
Reflecting on her journey, Ridgard shares, “This moment signifies a culmination of rigorous studying, dedication and perseverance in mastering business fundamentals, leadership skills and strategic thinking.” Her pursuit of an MBA stemmed from a pivotal moment in her career when she was promoted at the Centre for Teaching and Learning (CTL) at UFS. Tasked with leading a group of young people Ridgard recognised the need to augment her knowledge to effectively guide her colleagues. The MBA became her vehicle for professional growth, extending beyond a mere qualification to a profound transformation of her leadership capabilities.
“Attaining an MBA milestone represents a transformative experience that has shaped my thinking to make impactful contributions in any future landscape,” Ridgard explains. Her experience not only enhanced her strategic acumen but also deepened her understanding of organisational dynamics. She acknowledges the pivotal role played by the UFS Business School in nurturing her journey towards academic and personal success.
What to expect from Ridgard
Looking ahead, Ridgard’s commitment to continuous learning remains unwavering. Selected as one of five MBA students to address the 17th International Business Conference (IBC) in September 2024, she eagerly anticipates the opportunity to share insights on her work titled, “Next-Gen Integration: Navigating the Onboarding Maze for Gen Z in Today's Workplace.” Despite her current responsibilities at UJ, she harbors plans to pursue a PhD in the near future.
Amidst her ambitious pursuits, Ridgard remains grounded, prioritising the celebration of her MBA achievement. ‘’As everyone dreams about it, I just want to walk over that stage in a black gown and a hood on my head with my loved ones cheering me on,’’ she shared.
Ridgard’s journey serves as a beacon of inspiration, exemplifying the transformative potential of education and the enduring impact of determined leadership. Her story reminds us that true leadership is not merely about reaching milestones but also about empowering others and embracing continuous growth.
UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08
The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.
The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.
The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.
“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.
“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.
According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.
The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.
According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.
The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.
Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004